|
1
|
Polascik TJ, Oesterling JE and Partin AW:
Prostate specific antigen: a decade of discovery - what we have
learned and where we are going. J Urol. 162:293–306. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kinoshita H, Kamoto T, Nishiyama H,
Nakamura E, Matsuda T and Ogawa O: Prostate specific antigen nadir
determined using ultra-sensitive prostate specific antigen as a
predictor of biochemical progression after radical prostatectomy in
Japanese males. Int J Urol. 14:930–934. 2007. View Article : Google Scholar
|
|
3
|
Ellis WJ, Vessella RL, Noteboom JL, Lange
PH, Wolfert RL and Rittenhouse HG: Early detection of recurrent
prostate cancer with an ultrasensitive chemiluminescent
prostate-specific antigen assay. Urology. 50:573–579. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu H, Diamandis EP, Prestigiacomo AF and
Stamey TA: Ultrasensitive assay of prostate-specific antigen used
for early detection of prostate cancer relapse and estimation of
tumor-doubling time after radical prostatectomy. Clin Chem.
41:430–434. 1995.
|
|
5
|
Haese A, Huland E, Graefen M, Hammerer P,
Noldus J and Huland H: Ultrasensitive detection of prostate
specific antigen in the followup of 422 patients after radical
prostatectomy. J Urol. 161:1206–1211. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sandler HM and Eisenberger MA: Assessing
and treating patients with increasing prostate specific antigen
following radical prostatectomy. J Urol. 178:S20–S24. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naito S: Evaluation and management of
prostate-specific antigen recurrence after radical prostatectomy
for localized prostate cancer. Jpn J Clin Oncol. 35:365–374. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mottet N, Bellmunt J, Bolla M, et al: EAU
guidelines on prostate cancer. Part II: Treatment of advanced,
relapsing, and castration-resistant prostate cancer. Eur Urol.
59:572–583. 2011. View Article : Google Scholar
|
|
9
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL; ISUP Grading Committee. The 2005 International Society
of Urological Pathology (ISUP) consensus conference on Gleason
grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th edition.
Wiley-Blackwell; Oxford: 2009
|
|
11
|
Thompson IM, Tangen CM, Paradelo J, et al:
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer
significantly reduces risk of metastases and improves survival:
long-term followup of a randomized clinical trial. J Urol.
181:956–962. 2009. View Article : Google Scholar
|
|
12
|
Bolla M, van Poppel H, Tombal B, et al:
Postoperative radiotherapy after radical prostatectomy for
high-risk prostate cancer: long-term results of a randomised
controlled trial (EORTC trial 22911). Lancet. 380:2018–2027. 2012.
View Article : Google Scholar
|
|
13
|
Shen S, Lepor H, Yaffee R and Taneja SS:
Ultrasensitive serum prostate specific antigen nadir accurately
predicts the risk of early relapse after radical prostatectomy. J
Urol. 173:777–780. 2005. View Article : Google Scholar
|
|
14
|
Nakamura M, Hasumi H, Miyoshi Y, Sugiura
S, Fujinami K, Yao M, Kubota Y and Uemura H: Usefulness of
ultrasensitive prostate-specific antigen assay for early detection
of biochemical failure after radical prostatectomy. Int J Urol.
12:1050–1054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bader P, Burkhard FC, Markwalder R and
Studer UE: Disease progression and survival of patients with
positive lymph nodes after radical prostatectomy. Is there a chance
of cure? J Urol. 169:849–854. 2003. View Article : Google Scholar
|
|
16
|
Shimizu F, Tanaka S, Matsuyama Y, Tominaga
T, Ohashi Y and Fujime M: Efficiency of ultrasensitive
prostate-specific antigen assay in diagnosing biochemical failure
after radical prostatectomy. Jpn J Clin Oncol. 37:446–451. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Terai A, Matsui Y, Yoshimura K, Arai Y and
Dodo Y: Salvage radiotherapy for biochemical recurrence after
radical prostatectomy. BJU Int. 96:1009–1013. 2005. View Article : Google Scholar : PubMed/NCBI
|
